Novo Nordisk A/S (NVO) Earnings Call Analysis
NYSE · Unknown · Unknown
Next earnings call: 2026-08-05
(Q2 2026)
— full calendar
Earnings Reports
-
Novo Nordisk (NVO) Q4 2025: Obesity Pill Launch Drives 134% Wegovy Growth, But 2026 Guides to Double-Digit U.S. Decline
June 15, 2026
-
Novo Nordisk (NVO) Q1 2026: Obesity Care Sales Jump 22% as Oral Wegovy Redefines Category
May 06, 2026
-
Novo Nordisk (NVO) Q3 2025: 9,000 Job Cuts Unlock DKK 8B for Obesity and Diabetes Focus
November 05, 2025
-
Novo Nordisk (NVO) Q2 2025: CapEx Climbs 49% as Supply Expansion Targets Global GLP-1 Demand
August 06, 2025
-
Novo Nordisk (NVO) Q1 2025: Strong 18% Growth as GLP-1 Compounding Clouds U.S. Outlook
June 10, 2025